Rimmel London
- Manufacturer
- Lancaster S.A.M. | Rimmel Inc.
- Effective date
- 2010-10-20
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 3
- Source
- full-release
- Hydrated at
- 2026-05-31 22:29:55
Label at a glance#
Label contents#
Full prescribing information#
WARNINGS SECTION
OTC - ACTIVE INGREDIENT SECTION
INACTIVE INGREDIENT SECTION
COSMETIC INGREDIENTS: POLYBUTENE, HYDROGENATED
POLYISOBUTENE, PARAFFINUM LIQUIDUM/MINERAL OIL/
HUILE MINERALE, ETHYLHEXYL PALMITATE, LANOLIN OIL,
ETHYLENE/PROPYLENE/STYRENE COPOLYMER, POLYETHYLENE,
CALCIUM ALUMINUM BOROSILICATE, SILICA DIMETHYL
SILYLATE, SILICA, SYNTHETIC FLUORPHLOGOPITE,
ISOPROPYLPARABEN,BUTYLENE/ETHYLENE/STYRENE
COPOLYMER, TOCOPHERYL ACETATE, PENTAERYTHRITYL
TETRAISOSTEARATE, BUTYLPARABEN, ISOBUTYLPARABEN,
PARFUM/FRAGRANCE, TRIBEHENIN, CARMINE, LINALOOL, BHT,
ASCORBYL PALMITATE, RETINYL PALMITATE, TIN OXIDE,
HYDROXYCITRONELLAL, SORBITAN ISOSTEARATE, HEXYL
CINNAMAL, BUTYLENE GLYCOL, PALMITIC ACID,
PHENOXYETHANOL, METHYLPARABEN, SODIUM CHONDROITIN
SULFATE, PROPYLPARABEN, CAPRYLYL GLYCOL, ATELOCOLLAGEN,
SODIUM HYALURONATE, HEXYLENE GLYCOL, PALMITOYL
OLIGOPEPTIDE, ETHYLPARABEN. [MAY CONTAIN/PEUT CONTENIR/
: MICA, TITANIUM DIOXIDE (CI 77891), IRON OXIDES
(CI 77491, CI 77492, CI 77499), DandC RED NO. 7 CALCIUM LAKE
(CI 15850), DandC RED NO. 6 BARIUM LAKE (CI 15850), FDandC
YELLOW NO. 5 ALUMINUM LAKE (CI 19140), DandC RED NO. 33
ALUMINUM LAKE (CI 17200), FDandC BLUE NO. 1 ALUMINUM LAKE
CI 42090), FDandC YELLOW NO. 6 ALUMINUM LAKE (CI 15985),
DandC RED NO. 27 ALUMINUM LAKE (CI 45410)].
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
RIMMEL LONDON
SPF 15 SUNSCREEN
MOISTURE RENEW
WITH COLLAGEN AND VITAMINS A, C and E
CREAM LIPGLOSS
0.20 fl oz 6 ml
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 95250459-30e4-45c1-b08a-993044f49109 | Product name | 2 | 20250805 |
| 910c1bd7-67d1-44c7-ad4f-9445f827edcc | Product name | 1 | 20230808 |
| 26acd337-b838-40ac-bcbc-05c3b81c8712 | Product name | 1 | 20170323 |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 59351-0306-1 | 2019-11-13 | C162847 | 48780-1 | 97449f38-b9f3-f6ea-e053-dbdaa90aa703 | Rimmel London Moisture Renew Lipgloss Active Mauve (135) SPF 15 Sunscreen |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 59351-0306-1 | Rimmel LondonMoisture Renew Lipgloss - Active Mauve (135) | 6 mL in 1 TUBE | CREAM | 6 | 3 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 59351-0306 | RIMMEL LONDON MOISTURE RENEW LIPGLOSS - ACTIVE MAUVE (135) (OCTINOXATE, OCTISALATE) CREAM [LANCASTER S.A.M.] | 3 | Legacy NDC, 1 package rows | 20111028_6ccac972-96a6-4b0c-9f4a-9682441da4fa.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| OCTINOXATE | ACTIVE INGREDIENT | 4Y5P7MUD51 | 3 | |
| OCTISALATE | ACTIVE INGREDIENT | 4X49Y0596W | 3 | |
| OCTINOXATE | ACTIVE MOIETY | 4Y5P7MUD51 | 3 | |
| OCTISALATE | ACTIVE MOIETY | 4X49Y0596W | 3 | |
| .ALPHA.-HEXYLCINNAMALDEHYDE | INACTIVE INGREDIENT | 7X6O37OK2I | 3 | |
| .ALPHA.-TOCOPHEROL ACETATE, D- | INACTIVE INGREDIENT | A7E6112E4N | 3 | |
| ALUMINUM | INACTIVE INGREDIENT | CPD4NFA903 | 3 | |
| ASCORBYL PALMITATE | INACTIVE INGREDIENT | QN83US2B0N | 3 | |
| BARIUM | INACTIVE INGREDIENT | 24GP945V5T | 3 | |
| BUTYLATED HYDROXYTOLUENE | INACTIVE INGREDIENT | 1P9D0Z171K | 3 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 3 | |
| BUTYLPARABEN | INACTIVE INGREDIENT | 3QPI1U3FV8 | 3 | |
| CALCIUM | INACTIVE INGREDIENT | SY7Q814VUP | 3 | |
| CAPRYLYL GLYCOL | INACTIVE INGREDIENT | 00YIU5438U | 3 | |
| ETHYLENE | INACTIVE INGREDIENT | 91GW059KN7 | 3 | |
| ETHYLHEXYL PALMITATE | INACTIVE INGREDIENT | 2865993309 | 3 | |
| ETHYLPARABEN | INACTIVE INGREDIENT | 14255EXE39 | 3 | |
| HEXYLENE GLYCOL | INACTIVE INGREDIENT | KEH0A3F75J | 3 | |
| HYALURONATE SODIUM | INACTIVE INGREDIENT | YSE9PPT4TH | 3 | |
| HYDROXYCITRONELLAL | INACTIVE INGREDIENT | 8SQ0VA4YUR | 3 | |
| IRON | INACTIVE INGREDIENT | E1UOL152H7 | 3 | |
| ISOBUTYLPARABEN | INACTIVE INGREDIENT | 0QQJ25X58G | 3 | |
| ISOPROPYLPARABEN | INACTIVE INGREDIENT | A6EOX47QK0 | 3 | |
| LANOLIN | INACTIVE INGREDIENT | 7EV65EAW6H | 3 | |
| LINALOOL, (+/-)- | INACTIVE INGREDIENT | D81QY6I88E | 3 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 3 | |
| MICA | INACTIVE INGREDIENT | V8A1AW0880 | 3 | |
| MINERAL OIL | INACTIVE INGREDIENT | T5L8T28FGP | 3 | |
| PALMITIC ACID | INACTIVE INGREDIENT | 2V16EO95H1 | 3 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 3 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 3 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 3 | |
| SORBITAN | INACTIVE INGREDIENT | 6O92ICV9RU | 3 | |
| STANNIC OXIDE | INACTIVE INGREDIENT | KM7N50LOS6 | 3 | |
| SULFATE ION | INACTIVE INGREDIENT | 7IS9N8KPMG | 3 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 3 | |
| TRIBEHENIN | INACTIVE INGREDIENT | 8OC9U7TQZ0 | 3 | |
| VITAMIN A PALMITATE | INACTIVE INGREDIENT | 1D1K0N0VVC | 3 |
Products#
Every source-derived product name is available through these pages.
- Rimmel London Moisture Renew Lipgloss - Active Mauve (135)
- Octinoxate, Octisalate
- OCTINOXATE
- OCTISALATE
- MINERAL OIL
- ETHYLHEXYL PALMITATE
- LANOLIN
- ETHYLENE
- ALUMINUM
- SILICON DIOXIDE
- ISOPROPYLPARABEN
- .ALPHA.-TOCOPHEROL ACETATE, D-
- BUTYLPARABEN
- ISOBUTYLPARABEN
- TRIBEHENIN
- LINALOOL, (+/-)-
- BUTYLATED HYDROXYTOLUENE
- ASCORBYL PALMITATE
- VITAMIN A PALMITATE
- STANNIC OXIDE
- HYDROXYCITRONELLAL
- SORBITAN
- .ALPHA.-HEXYLCINNAMALDEHYDE
- BUTYLENE GLYCOL
- PALMITIC ACID
- PHENOXYETHANOL
- METHYLPARABEN
- SULFATE ION
- PROPYLPARABEN
- CAPRYLYL GLYCOL
- HYALURONATE SODIUM
- HEXYLENE GLYCOL
- ETHYLPARABEN
- MICA
- TITANIUM DIOXIDE
- IRON
- CALCIUM
- BARIUM
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 59351-0306 | 59351-0306-1 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / OPHTHALMIC | 0.05 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CREAM / TOPICAL | 6 mg | ||
| SORBITAN | SORBITAN | 6O92ICV9RU | CAPSULE / ORAL | 19.08 mg | ||
| BUTYLPARABEN | BUTYLPARABEN | 3QPI1U3FV8 | DROPS / ORAL | NA | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL, FOAM / TOPICAL | 72 mg | ||
| BUTYLPARABEN | BUTYLPARABEN | 3QPI1U3FV8 | TABLET / ORAL | NA | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 0.4 mg | ||
| BUTYLPARABEN | BUTYLPARABEN | 3QPI1U3FV8 | CREAM / TOPICAL | 0.4 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / TOPICAL | 24 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SYSTEM / TOPICAL | 42 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / INTRAVENOUS | 0.02 %w/v | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | FILM, SOLUBLE / ORAL | 0.06 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | DROPS / ORAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, DELAYED RELEASE / ORAL | 66 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET, FOR SUSPENSION / ORAL | 0.1 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / NASAL | 20 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | GEL / TOPICAL | 463 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| BUTYLPARABEN | BUTYLPARABEN | 3QPI1U3FV8 | SOLUTION / ORAL | 6 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | DROPS / ORAL | NA | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SWAB / TOPICAL | 0.5 %w/w | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET / ORAL | 3 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAVENOUS | 0.13 %w/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CAPSULE / ORAL | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER, FOR SUSPENSION / ORAL | 297 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | DROPS / ORAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | GRANULE, FOR SUSPENSION / ORAL | 143 mg | ||
| BUTYLPARABEN | BUTYLPARABEN | 3QPI1U3FV8 | TABLET, EXTENDED RELEASE / ORAL | 0.01 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / BUCCAL | 3 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| ASCORBYL PALMITATE | ASCORBYL PALMITATE | QN83US2B0N | CAPSULE / ORAL | 12 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | FILM / BUCCAL | 0.22 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, EXTENDED RELEASE / ORAL | 0.17 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL / TOPICAL | 1.05 %w/w | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | INSERT, EXTENDED RELEASE / OPHTHALMIC | 0.4 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAMUSCULAR | 23 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUPPOSITORY / VAGINAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM, AUGMENTED / TOPICAL | 2 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OIL / TOPICAL | 43.29 %v/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | OINTMENT / TOPICAL | 5 %w/w | ||
| ETHYLPARABEN | ETHYLPARABEN | 14255EXE39 | SOLUTION / ORAL | 14 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SOAP / TOPICAL | 1 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | INJECTION / INTRAVENOUS | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / ORAL | 2 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / PARENTERAL | 18 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / AURICULAR (OTIC) | 0.01 %w/w | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | OINTMENT / TOPICAL | 57 mg | ||
| BUTYLPARABEN | BUTYLPARABEN | 3QPI1U3FV8 | SOLUTION / RECTAL | 0.01 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / VAGINAL | 8 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUSPENSION / OPHTHALMIC | 0.1 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET / ORAL | 1.8 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.16 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / ORAL | 346 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, CHEWABLE / ORAL | 6 mg | ||
| HEXYLENE GLYCOL | HEXYLENE GLYCOL | KEH0A3F75J | OINTMENT / TOPICAL | 12 %w/w |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| bb14a74d-47c2-4f7d-bdb5-beb04ae80574 | 6ccac972-96a6-4b0c-9f4a-9682441da4fa | 2010-10-20 | Warnings | bb14a74d-47c2-4f7d-bdb5-beb04ae80574 6ccac972-96a6-4b0c-9f4a-9682441da4fa |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.


